Beta Drugs Ltd
BETABeta Drugs Ltd
BETA
Price Chart
Scorecard
Performance
AvgPrice return has been average, nothing exciting
Valuation
HighSeems to be overvalued vs the market average
Growth
AvgFinancials growth has been moderate for a few years
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is overpriced but is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| — | 12.36 | — |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 51.49 | 6.67 | 0.52% |
Forecast & Ratings
Detailed Forecast Price
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
Beta Drugs Limited is a pharmaceutical formulation manufacturing company. It is engaged in developing, manufacturing and marketing of drug products for domestic and international customers. The Company also engaged manufacturing oncology products
Peers
Compare with peersSun Pharmaceutical Industries Ltd
Cipla Ltd
Mankind Pharma Ltd
Torrent Pharmaceuticals Ltd
Dr Reddy's Laboratories Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
Hmm, looks like data is unavailable here. Please come back after some timeRevenue Forecast
Hmm, looks like data is unavailable here. Please come back after some timeEarnings Per Share Forecast
Hmm, looks like data is unavailable here. Please come back after some timeIncome
Balance Sheet
Cash Flow
Income Statement
| Financial Year | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 50.81 | 66.30 | 91.22 | 116.62 | 184.60 | 227.86 | 297.07 | — | ||||||||
Raw Materials | 28.15 | 37.26 | 45.21 | 60.55 | 96.21 | 110.40 | 167.65 | — | ||||||||
| Power & Fuel Cost | 0.89 | 1.21 | 1.95 | 2.75 | 3.43 | 4.79 | 6.35 | |||||||||
| Employee Cost | 1.26 | 3.80 | 6.95 | 8.32 | 12.10 | 17.08 | 20.14 | |||||||||
| Selling & Administrative Expenses | 4.85 | 7.82 | 10.27 | 10.31 | 16.26 | 25.89 | 33.12 | |||||||||
| Operating & Other expenses | 5.96 | 4.04 | 8.52 | 9.45 | 13.14 | 15.83 | 8.46 | |||||||||
EBITDA | 9.70 | 12.17 | 18.32 | 25.24 | 43.46 | 53.87 | 61.35 | — | ||||||||
| Depreciation/Amortization | 1.85 | 2.84 | 3.76 | 6.87 | 7.25 | 10.41 | 9.78 | — | ||||||||
| PBIT | 7.85 | 9.33 | 14.56 | 18.37 | 36.21 | 43.46 | 51.57 | — | ||||||||
| Interest & Other Items | 1.01 | 1.43 | 2.59 | 2.42 | 1.90 | 2.41 | 2.82 | — | ||||||||
| PBT | 6.84 | 7.90 | 11.97 | 15.95 | 34.31 | 41.05 | 48.75 | — | ||||||||
| Taxes & Other Items | 0.07 | -0.14 | 2.56 | 4.23 | 9.48 | 10.34 | 12.32 | — | ||||||||
| Net Income | 6.77 | 8.04 | 9.41 | 11.72 | 24.83 | 30.71 | 36.43 | — | ||||||||
| EPS | 7.83 | 9.30 | 10.30 | 12.19 | 25.83 | 31.94 | 37.89 | — | ||||||||
| DPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | ||||||||
| Payout ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Company Updates
Peers & Comparison
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Beta Drugs Ltd | 53.31 | 12.36 | — |
| Sun Pharmaceutical Industries Ltd | 46.13 | 6.58 | 0.73% |
| Cipla Ltd | 29.21 | 4.49 | 0.87% |
| Mankind Pharma Ltd | 62.91 | 12.57 | — |
Price Comparison
Compare BETA with any stock or ETFShareholdings
Promoter Holdings Trend
Total Promoter Holding
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Pledged promoter holdings is insignificant
Institutional Holdings Trend
Total Retail Holding
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
In last 3 months, foreign institutional holding of the company has almost stayed constant
Shareholding Pattern
Mar 2024
Jun 2024
Sep 2024
Nov 2024
Shareholding History
Hmm, looks like there hasn't been any net deal activity in the last 6 monthssmallcases
Looks like this stock is not in any smallcase yet.
Events
Dividend Trend
No Dividends
BETA has not given any dividends in last 5 years
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
Hmm, looks like data is unavailable here. Please come back after some timeBeta Drugs announced that an Extra Ordinary General Meeting (EGM) of the Company will be held on 21 December 2024 .Powered by Capital Market - Live
Beta Drugs will hold a meeting of the Board of Directors of the Company on 6 November 2024Powered by Capital Market - Live
Beta Drugs announced that an Extra Ordinary General Meeting (EGM) of the Company will be held on 12 November 2024 .Powered by Capital Market - Live
Beta Drugs announced that the 19th Annual General Meeting (AGM) of the company will be held on 30 September 2024.Powered by Capital Market - Live
Stock market update: Stocks that hit 52-week highs on NSE
Higher than Industry Revenue Growth
Over the last 5 years, revenue has grown at a yearly rate of 34.98%, vs industry avg of 9.04%
Increasing Market Share
Over the last 5 years, market share increased from 0.03% to 0.08%
Higher than Industry Net Income
Over the last 5 years, net income has grown at a yearly rate of 35.28%, vs industry avg of 15.28%